Dr Max Taquet, Clinical Lecturer at the University of Oxford and senior author of the study, added: Our study is observational and these results should therefore be replicated in a randomised controlled trial to confirm and extend our findings. Nevertheless, they are good news for patients with psychiatric disorders, who are at an increased risk of diabetes. While semaglutide is also used in people with obesity, with most diabetes patients with type 2 diabetes also presenting being overweight or obese, the findings from this study cannot be applied to people who do not have diabetes.
Therefore, MedTech companies should focus on the five essential steps mentioned before to prepare for success in a healthcare landscape directly shaped by GLP-1 advancements
For newer medications like semaglutide and tirzepatide, that average was higher, approximately 0.8 kg per month
CLICK HERE TO DOWNLOAD THE FOX NEWS APP "Additionally, side effects of weight-loss medications, such as nausea, fatigue or gastrointestinal discomfort, may further reduce a person's ability or desire to be physically active," the expert added
Kidney Function Protection Studies have shown that GLP1 can help reduce markers of kidney disease progression in diabetic patients
00125-7/asset/85fa7e17-4785-4f71-9b61-806d7ecb7b4a/main.assets/gr2_lrg.jpg)
